Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.

IF 8.2 1区 医学 Q1 IMMUNOLOGY
Erick Auma, Rencia Alberts, Brigitta Derendinger, Rouxjeane Venter, Elizabeth M Streicher, Samantha Pillay, Yonas T Ghebrekristos, Moses Mburu, Morten Ruhwald, Robin Warren, Adam Penn-Nicholson, Grant Theron, Margaretha de Vos
{"title":"Diagnostic accuracy of LiquidArray MTB-XDR VER1.0 for the detection of Mycobacterium tuberculosis complex, fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility.","authors":"Erick Auma, Rencia Alberts, Brigitta Derendinger, Rouxjeane Venter, Elizabeth M Streicher, Samantha Pillay, Yonas T Ghebrekristos, Moses Mburu, Morten Ruhwald, Robin Warren, Adam Penn-Nicholson, Grant Theron, Margaretha de Vos","doi":"10.1093/cid/ciae614","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exists for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (latter two have no rapid DSTs available).</p><p><strong>Methods: </strong>We enrolled people (n=720) with presumptive TB who provided two sputa for a Xpert MTB/RIF Ultra and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract-fleXT (fleXT) DNA extraction methods were compared.</p><p><strong>Results: </strong>For MTBC, LA-XDR had similar sensitivities (85-87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities varied: 94% (95% CI: 86, 98) for fluoroquinolones, 64% (45, 80) for amikacin, and 88% (79, 93) for ethambutol (specificities 97-100%). 6/7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates higher with Fluorolyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 24/100 (24%) would be missed (one extraction error, two invalid results, 15 MTBC-negative, six fluoroquinolone-indeterminate, one false-susceptible).</p><p><strong>Conclusion: </strong>LA-XDR met the minimum WHO target product profile for a next-generation sputum-based moderate complexity DST with high fluoroquinolones and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae614","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exists for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (latter two have no rapid DSTs available).

Methods: We enrolled people (n=720) with presumptive TB who provided two sputa for a Xpert MTB/RIF Ultra and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract-fleXT (fleXT) DNA extraction methods were compared.

Results: For MTBC, LA-XDR had similar sensitivities (85-87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities varied: 94% (95% CI: 86, 98) for fluoroquinolones, 64% (45, 80) for amikacin, and 88% (79, 93) for ethambutol (specificities 97-100%). 6/7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates higher with Fluorolyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 24/100 (24%) would be missed (one extraction error, two invalid results, 15 MTBC-negative, six fluoroquinolone-indeterminate, one false-susceptible).

Conclusion: LA-XDR met the minimum WHO target product profile for a next-generation sputum-based moderate complexity DST with high fluoroquinolones and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.

LiquidArray MTB-XDR VER1.0检测结核分枝杆菌复体、氟喹诺酮、阿米卡星、乙胺丁醇和利奈唑胺药敏的诊断准确性
背景:药敏试验(DST)对于开始有效的结核病(TB)治疗方案至关重要。目前尚无高通量LiquidArray MTB-XDR (LA-XDR)检测数据,该检测可检测结核分枝杆菌复合体(MTBC)和氟喹诺酮、阿米卡星、乙胺丁醇和利奈唑胺的敏感性(后两者没有快速DSTs可用)。方法:我们招募了假定患有结核病的患者(n=720),他们提供了两份痰,用于Xpert MTB/RIF Ultra和培养(MTBC参考标准)。表型DST和Sanger测序为综合参考标准。比较了LA-XDR对手动FluoroLyse和自动GenoXtract-fleXT (fleXT) DNA提取方法的影响。结果:两种提取方法对MTBC的敏感性(85 ~ 87%)和特异性(99%)相似。药物敏感性各不相同:氟喹诺酮类药物为94% (95% CI: 85,98),阿米卡星为64%(45,80),乙胺丁醇为88%(79,93)(特异性97-100%)。检出耐药利奈唑胺6株(86%)。氟喹诺酮类、乙胺丁醇、阿米卡星和利奈唑胺的LA-XDR与fleXT的不确定比例分别为21/251(8%)、2/251(1%)、63/251(25%)和93/251(37%),其中阿米卡星和利奈唑胺与氟溶酶提取的DNA的不确定比例更高。假设有100名涂片阴性的耐氟喹诺酮类结核病患者接受fleXT DNA提取,其中24/100(24%)将被遗漏(1例提取错误,2例无效结果,15例mtbc阴性,6例氟喹诺酮不确定,1例假敏感)。结论:LA-XDR满足世卫组织新一代基于痰的中等复杂性DST的最低目标产品要求,具有高氟喹诺酮类药物和乙胺丁醇耐药敏感性,中等阿米卡星耐药敏感性,并有望对利奈唑胺耐药,这需要更多的数据。改进的LA-XDR MTBC检测将减少漏药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Infectious Diseases
Clinical Infectious Diseases 医学-传染病学
CiteScore
25.00
自引率
2.50%
发文量
900
审稿时长
3 months
期刊介绍: Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信